Study first
Clea reviews study identity, registry/ethics status and recruitment materials before promotion.
Make migraine research
easier to reach.
Clea can help legitimate research teams make eligible Australians aware of migraine studies. The commercial model never includes selling Clea's patient database.
Recruitment with an editorial firewall.
Research partnerships can strengthen the migraine ecosystem without changing Clea's treatment content, evidence summaries or provider rankings.
Participant choice
Members opt in to learn about or participate in a specific study. Their health record is not silently transferred.
No database sale
Research partners do not buy a list of Clea members or unrestricted access to longitudinal records.
Clear sponsorship
Paid recruitment or research partnerships are disclosed as commercial relationships.
Protocol controls data
Any identifiable information shared with a research team follows the study protocol and participant consent.
No editorial leverage
Funding a study or recruitment campaign does not buy favourable Clea clinical content.
Participant recruitment
Surface an approved recruiting study to potentially relevant audiences, without disclosing Clea member identities by default.
Research awareness
Explain a study, program or registry in plain language and link people to the official recruitment pathway.
Study design insight
Where appropriate, support patient-informed study communications or feasibility work under a defined scope.
De-identified insights
Future aggregate research products only where lawful, consent-compatible and independently governed. Never individual health-data sale.
RESEARCH ENQUIRY
Tell Clea about the study first.
Submission is not approval. Studies involving participant recruitment should have appropriate ethics/registry status and a clear consent/data pathway.